References

1. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. The Lancet. 2010;375:1545-1555.

2. Hall CB. Respiratory syncytial virus in young children. The Lancet. 2010;375(9725):1500-1502.


Continue Reading

3. Higgins D, Trujillo C, Keech C. Advances in RSV vaccine research and development—a global agenda. Vaccine. 2016;34(26):2870-5. doi:10.1016/j.vaccine.2016.03.109.

4. US Centers for Disease Control and Prevention (CDC). Respiratory syncytial virus (RSV). http://www.cdc.gov/rsv/index.html. Accessed July 17, 2016.

5. US Centers for Disease Control and Prevention (CDC). Guidelines for preventing health-care-associated pneumonia, 2003. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5303a1.htm. Accessed July 17, 2016.

6. Mazur NI, Martinón-Torres F, Baraldi E, et al. Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics. The Lancet Respiratory Medicine. 2015;3:888-900. doi:10.1016/S2213-2600(15)00255-6.

7. Stagliano DR, Nylund CM, Eide MB, Eberly MD. Children with Down syndrome are high-risk for severe respiratory syncytial virus disease. Journal of Pediatrics. 2015;166:703-709.

8. American Academy of Pediatrics (AAP). Policy statement. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134(2):415-420. http://pediatrics.aappublications.org/content/134/2/415.full. Accessed July 17, 2016.

9. Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalizations from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531-537.

10. DeVincenzo JP, McClure MW, Symons JA, et al. Activity of oral ALS-008176 in a respiratory syncytial virus challenge study. New England Journal of Medicine. 2015;373:2048-2058. http://www.nejm.org/doi/pdf/10.1056/NEJMoa1413275. Accessed July 17, 2016.

11. Simões EAF, DeVincenzo JP, Boeckh M, et al. Challenges and opportunities in developing respiratory syncytial virus therapeutics. Journal of Infectious Diseases. 2015;211(S1):S1-S20.

12. Mazur NI, van Delden JJM, Bont LJ. Respiratory syncytial virus trials and beyond. The Lancet Infectious Diseases. 2015;15:1363-1365. doi:10.1016/S1473-3099(15)00304-7.

13. O’Brien K, Chandran A, Weatherholtz R, et al. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial. The Lancet Infectious Diseases. 2015;15:1398-1408. doi:10.1016/S1473-3099(15)00247-9.